Equities analysts expect that Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) will report $2.26 million in sales for the current quarter, according to Zacks. Three analysts have issued estimates for Tetraphase Pharmaceuticals’ earnings, with estimates ranging from $1.50 million to $3.28 million. Tetraphase Pharmaceuticals reported sales of $1.09 million in the same quarter last year, which would suggest a positive year over year growth rate of 107.3%. The business is scheduled to announce its next quarterly earnings results on Wednesday, March 14th.

According to Zacks, analysts expect that Tetraphase Pharmaceuticals will report full-year sales of $2.26 million for the current fiscal year, with estimates ranging from $6.00 million to $10.41 million. For the next financial year, analysts anticipate that the firm will report sales of $6.58 million per share, with estimates ranging from $5.00 million to $12.41 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that cover Tetraphase Pharmaceuticals.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) EPS for the quarter, meeting analysts’ consensus estimates of ($0.63). Tetraphase Pharmaceuticals had a negative return on equity of 88.27% and a negative net margin of 1,382.33%. The company had revenue of $4.10 million during the quarter, compared to analysts’ expectations of $1.59 million. During the same period last year, the business posted ($0.58) EPS. Tetraphase Pharmaceuticals’s revenue for the quarter was up 355.6% on a year-over-year basis.

A number of equities analysts recently commented on TTPH shares. BidaskClub upgraded Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, August 22nd. Piper Jaffray Companies started coverage on Tetraphase Pharmaceuticals in a report on Monday, August 28th. They set an “overweight” rating and a $14.00 target price for the company. Zacks Investment Research cut Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, August 30th. ValuEngine cut Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, September 1st. Finally, Stifel Nicolaus restated a “buy” rating and set a $13.00 target price on shares of Tetraphase Pharmaceuticals in a report on Tuesday, September 12th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company’s stock. Tetraphase Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $15.15.

In related news, Director L Patrick Gage acquired 3,880 shares of the firm’s stock in a transaction dated Wednesday, November 29th. The stock was acquired at an average price of $6.45 per share, for a total transaction of $25,026.00. Following the purchase, the director now owns 38,880 shares of the company’s stock, valued at approximately $250,776. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Jacques Dumas sold 8,750 shares of Tetraphase Pharmaceuticals stock in a transaction dated Tuesday, October 31st. The shares were sold at an average price of $6.03, for a total value of $52,762.50. Following the completion of the transaction, the insider now owns 8,750 shares of the company’s stock, valued at approximately $52,762.50. The disclosure for this sale can be found here. Company insiders own 5.50% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Cubist Systematic Strategies LLC purchased a new position in shares of Tetraphase Pharmaceuticals in the 3rd quarter valued at about $195,000. California State Teachers Retirement System raised its position in shares of Tetraphase Pharmaceuticals by 20.1% during the 3rd quarter. California State Teachers Retirement System now owns 80,471 shares of the biopharmaceutical company’s stock worth $550,000 after acquiring an additional 13,451 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Tetraphase Pharmaceuticals by 32.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,461,807 shares of the biopharmaceutical company’s stock worth $9,998,000 after acquiring an additional 360,552 shares in the last quarter. Schwab Charles Investment Management Inc. raised its position in shares of Tetraphase Pharmaceuticals by 67.4% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 217,079 shares of the biopharmaceutical company’s stock worth $1,485,000 after acquiring an additional 87,398 shares in the last quarter. Finally, JPMorgan Chase & Co. acquired a new stake in shares of Tetraphase Pharmaceuticals during the 3rd quarter worth about $7,915,000. Institutional investors and hedge funds own 58.19% of the company’s stock.

Shares of Tetraphase Pharmaceuticals (NASDAQ TTPH) traded up $0.14 during trading on Friday, reaching $5.89. The company had a trading volume of 1,610,455 shares, compared to its average volume of 514,643. Tetraphase Pharmaceuticals has a 12 month low of $3.57 and a 12 month high of $9.93.

ILLEGAL ACTIVITY NOTICE: “Analysts Expect Tetraphase Pharmaceuticals, Inc. (TTPH) Will Announce Quarterly Sales of $2.26 Million” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at https://www.americanbankingnews.com/2017/12/16/analysts-expect-tetraphase-pharmaceuticals-inc-ttph-will-announce-quarterly-sales-of-2-26-million.html.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Get a free copy of the Zacks research report on Tetraphase Pharmaceuticals (TTPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.